OTIC [NASD]
Otonomy, Inc.
Index- P/E- EPS (ttm)-0.78 Insider Own1.60% Shs Outstand67.85M Perf Week12.79%
Market Cap107.30M Forward P/E- EPS next Y-0.77 Insider Trans-4.22% Shs Float55.75M Perf Month-15.28%
Income-52.50M PEG- EPS next Q-0.20 Inst Own64.00% Short Float0.91% Perf Quarter-4.43%
Sales0.12M P/S858.41 EPS this Y26.30% Inst Trans-0.10% Short Ratio3.13 Perf Half Y-9.77%
Book/sh0.64 P/B3.03 EPS next Y3.80% ROA-52.90% Target Price6.50 Perf Year-17.09%
Cash/sh- P/C- EPS next 5Y20.40% ROE-86.70% 52W Range1.14 - 2.59 Perf YTD-6.73%
Dividend- P/FCF- EPS past 5Y26.20% ROI-69.70% 52W High-25.09% Beta1.70
Dividend %- Quick Ratio- Sales past 5Y-28.80% Gross Margin- 52W Low70.18% ATR0.21
Employees51 Current Ratio6.60 Sales Q/Q-100.00% Oper. Margin- RSI (14)43.26 Volatility13.94% 10.64%
OptionableYes Debt/Eq0.38 EPS Q/Q14.40% Profit Margin- Rel Volume0.46 Prev Close1.87
ShortableYes LT Debt/Eq0.37 EarningsMay 09 AMC Payout- Avg Volume161.40K Price1.94
Recom1.80 SMA20-9.23% SMA50-13.84% SMA200-3.07% Volume74,796 Change3.74%
Jun-01-20Resumed Oppenheimer Outperform $8
Dec-24-19Initiated Oppenheimer Outperform $8
Mar-19-18Downgrade JP Morgan Neutral → Underweight
Mar-12-18Upgrade Piper Jaffray Neutral → Overweight
Aug-30-17Downgrade Piper Jaffray Overweight → Neutral
Aug-30-17Downgrade JP Morgan Overweight → Neutral
Aug-15-17Upgrade JP Morgan Neutral → Overweight
Jun-02-17Initiated Piper Jaffray Overweight $32
May-26-16Initiated WallachBeth Buy $29
Aug-10-15Upgrade Bernstein Mkt Perform → Outperform
May-22-15Downgrade JP Morgan Overweight → Neutral
May-18-22 07:30AM  
May-12-22 07:30AM  
May-09-22 09:00PM  
04:04PM  
May-02-22 07:30AM  
Apr-20-22 11:12AM  
07:30AM  
Mar-21-22 06:51PM  
Mar-15-22 07:30AM  
Feb-28-22 09:00PM  
04:27PM  
07:30AM  
Feb-25-22 07:30AM  
Feb-22-22 07:30AM  
Feb-17-22 07:30AM  
Feb-16-22 07:30AM  
Jan-25-22 07:30AM  
Jan-06-22 07:51AM  
Jan-03-22 07:30AM  
Nov-16-21 07:30AM  
Nov-10-21 07:05PM  
04:18PM  
Nov-03-21 07:30AM  
Oct-27-21 03:03PM  
07:30AM  
Oct-12-21 07:30AM  
Sep-27-21 07:30AM  
Sep-22-21 09:08AM  
Sep-02-21 07:30AM  
Aug-19-21 07:30AM  
Aug-04-21 06:45PM  
04:16PM  
Jul-28-21 07:30AM  
Jul-27-21 03:03PM  
Jun-16-21 02:05AM  
Jun-15-21 07:30AM  
May-14-21 02:59PM  
07:30AM  
May-11-21 04:17PM  
02:30PM  
May-04-21 07:30AM  
Apr-28-21 07:30AM  
Apr-19-21 07:30AM  
Apr-07-21 10:02PM  
04:06PM  
Apr-06-21 07:30AM  
Apr-05-21 07:30AM  
Mar-25-21 07:30AM  
Feb-26-21 11:01AM  
Feb-25-21 07:30AM  
Feb-22-21 09:32AM  
08:37AM  
07:23AM  
07:00AM  
Feb-17-21 07:30AM  
Feb-12-21 01:31AM  
Feb-11-21 04:17PM  
02:30PM  
Feb-04-21 07:30AM  
04:22AM  
Jan-05-21 07:30AM  
Dec-17-20 07:00AM  
Dec-15-20 07:50PM  
Dec-14-20 08:59AM  
Nov-30-20 07:30AM  
Nov-16-20 07:30AM  
Nov-06-20 09:03AM  
Nov-04-20 06:55PM  
05:03PM  
04:17PM  
02:30PM  
Oct-28-20 07:30AM  
Oct-02-20 07:30AM  
Sep-15-20 08:52AM  
Sep-10-20 08:41AM  
Sep-02-20 07:30AM  
Aug-17-20 03:30PM  
Aug-04-20 07:25PM  
04:22PM  
Aug-03-20 07:30AM  
Jul-28-20 04:05PM  
Jul-15-20 01:15PM  
Jul-13-20 04:01PM  
09:08AM  
Jul-09-20 09:00AM  
Jul-08-20 09:01PM  
Jul-07-20 10:44AM  
05:51AM  
Jul-06-20 04:04PM  
04:02PM  
Jun-30-20 11:42PM  
Jun-17-20 08:31AM  
Jun-15-20 04:05PM  
Jun-11-20 08:41AM  
07:30AM  
Jun-10-20 07:30AM  
Jun-08-20 07:30AM  
Jun-01-20 09:56AM  
May-28-20 08:32AM  
May-12-20 08:00AM  
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Meniere's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cayer Paul ECh. Financial & Business OffcrMar 28Sale2.415,62413,571223,787Mar 29 08:53 PM
Foster Alan CharlesChief Scientific OfficerMar 28Sale2.412,5596,175177,017Mar 29 08:54 PM
Savel Robert Michael IIChief Technical OfficerMar 28Sale2.413,3258,023145,735Mar 29 08:58 PM
Weber David AllenPresident & CEOMar 28Sale2.4111,24327,129377,499Mar 29 08:59 PM
Weber David AllenPresident & CEOMar 25Sale2.398,02619,166388,742Mar 29 08:59 PM
Savel Robert Michael IIChief Technical OfficerMar 25Sale2.392,3745,669149,060Mar 29 08:58 PM
Foster Alan CharlesChief Scientific OfficerMar 25Sale2.391,8274,363179,576Mar 29 08:54 PM
Cayer Paul ECh. Financial & Business OffcrMar 25Sale2.394,0159,588229,411Mar 29 08:53 PM